Literature DB >> 10885560

Multiple mechanisms underlie HLA dysregulation in cervical cancer.

C S Brady1, J S Bartholomew, D J Burt, M F Duggan-Keen, S Glenville, N Telford, A M Little, J A Davidson, P Jimenez, F Ruiz-Cabello, F Garrido, P L Stern.   

Abstract

The consistent dysregulation of HLA expression in cervical neoplasia is likely to influence the natural history of the disease and prospects for cell-mediated vaccine therapies. We have studied the underlying mechanisms in eight new cervical cancer cell lines derived from primary tumour biopsies. At least five independent mechanisms leading to changes in HLA expression were seen: HLA class I allelic transcription but no protein; abnormal HLA class I allelic transcription; no HLA-B locus transcription; loss of heterozygosity (LOH); no gammaIFN-mediated upregulation of HLA class I expression, and/or no interferon-gamma (gammaIFN)-mediated HLA class II induction. These were evident in different combinations in 7/8 cell lines showing that multiple, mostly irreversible mechanisms not overridden by gammaIFN, are responsible for HLA dysregulation in cervical neoplasia. Point mutations were responsible for lack of HLA-A2 expression in two cases. In cell line 808, the mutation encodes a stop codon in exon 3; in cell line 778, mutation of the first intron acceptor site leads to use of an alternative AG site in exon 2, resulting in a frameshift and a stop codon after the translation of only 38 amino acids. Tumour cells showing specific HLA class I loss may have selective advantage in the face of tumour-specific cytotoxic T cells (CTL). Such immune escape mechanisms present a major obstacle for the success of CTL-mediated therapies in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10885560     DOI: 10.1034/j.1399-0039.2000.550502.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  23 in total

1.  In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity.

Authors:  Juan J Montesinos; María de L Mora-García; Héctor Mayani; Eugenia Flores-Figueroa; Rosario García-Rocha; Guadalupe R Fajardo-Orduña; Marta E Castro-Manrreza; Benny Weiss-Steider; Alberto Monroy-García
Journal:  Stem Cells Dev       Date:  2013-06-14       Impact factor: 3.272

2.  Cancer mutational burden is shaped by G4 DNA, replication stress and mitochondrial dysfunction.

Authors:  Albino Bacolla; Zu Ye; Zamal Ahmed; John A Tainer
Journal:  Prog Biophys Mol Biol       Date:  2019-03-14       Impact factor: 3.667

3.  A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.

Authors:  Angelika B Riemer; Derin B Keskin; Guanglan Zhang; Maris Handley; Karen S Anderson; Vladimir Brusic; Bruce Reinhold; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2010-07-08       Impact factor: 5.157

4.  Oncostatin M treatment increases the responsiveness toward cisplatin-based chemoradiotherapy in cervical cancer cells in a STAT3-dependent manner.

Authors:  Russalina Stroeder; Barbara Walch-Rückheim; Jil Fischbach; Ingolf Juhasz-Böss; Christian Rübe; Erich-Franz Solomayer; Sigrun Smola
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

5.  Analysis of HLA-E expression in human tumors.

Authors:  Rosario Marín; Francisco Ruiz-Cabello; Susana Pedrinaci; Rosa Méndez; Pilar Jiménez; Daniel E Geraghty; Federico Garrido
Journal:  Immunogenetics       Date:  2003-01-30       Impact factor: 2.846

6.  Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma.

Authors:  Ekaterina S Jordanova; Katja Philippo; Marius J Giphart; Ed Schuuring; Philip M Kluin
Journal:  Immunogenetics       Date:  2003-05-17       Impact factor: 2.846

Review 7.  Development of therapeutic HPV vaccines.

Authors:  Cornelia L Trimble; Ian H Frazer
Journal:  Lancet Oncol       Date:  2009-10       Impact factor: 41.316

8.  Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.

Authors:  María de Lourdes Mora-García; Alfonso Duenas-González; Jorge Hernández-Montes; Erick De la Cruz-Hernández; Enrique Pérez-Cárdenas; Benny Weiss-Steider; Edelmiro Santiago-Osorio; Vianney Francisco Ortíz-Navarrete; Víctor Hugo Rosales; David Cantú; Marcela Lizano-Soberón; Martha Patricia Rojo-Aguilar; Alberto Monroy-García
Journal:  J Transl Med       Date:  2006-12-27       Impact factor: 5.531

9.  Therapeutic vaccines against human papillomavirus and cervical cancer.

Authors:  Angel Cid-Arregui
Journal:  Open Virol J       Date:  2009-10-23

10.  The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system.

Authors:  Agnieszka K Grabowska; Angelika B Riemer
Journal:  Open Virol J       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.